Literature DB >> 21390070

Intratumor RNA interference of cell cycle genes slows down tumor progression.

S Dharmapuri1, D Peruzzi, E Marra, F Palombo, A J Bett, S R Bartz, M Yong, G Ciliberto, N La Monica, C A Buser, C Toniatti, L Aurisicchio.   

Abstract

Small interfering RNAs (siRNAs) are emerging as promising therapeutic tools. However, the widespread clinical application of such molecules as modulators of gene expression is still dependent on several aspects that limit their bioavailability. One of the most promising strategies to overcome the barriers faced by gene silencing molecules involves the use of lipid-based nanoparticles (LNPs) and viral vectors, such as adenoviruses (Ads). The primary obstacle for translating gene silencing technology from an effective research tool into a feasible therapeutic strategy remains its efficient delivery to the targeted cell type in vivo. In this study, we tested the capability of LNPs and Ad to transduce and treat locally tumors in vivo. Efficient knockdown of a surrogate reporter (luciferase) and therapeutic target genes such as the kinesin spindle protein (KIF11) and polo-like kinase 1 were observed. Most importantly, this activity led to a cell cycle block as a consequence and slowed down tumor progression in tumor-bearing animals. Our data indicate that it is possible to achieve tumor transduction with si/short hairpin RNAs and further improve the delivery strategy that likely in the future will lead to the ideal non-viral particle for targeted cancer gene silencing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390070     DOI: 10.1038/gt.2011.27

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Directing neuronal differentiation of primary neural progenitor cells by gene knockdown approach.

Authors:  Wei Ching Low; Winifred Wing Yiu Yau; Lawrence W Stanton; Guillaume Marcy; Eyleen Goh; Sing Yian Chew
Journal:  DNA Cell Biol       Date:  2012-02-17       Impact factor: 3.311

Review 2.  Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.

Authors:  Bin Shi; Marc Abrams
Journal:  J Histochem Cytochem       Date:  2013-03-14       Impact factor: 2.479

Review 3.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

4.  In vivo screening of S100B inhibitors for melanoma therapy.

Authors:  Danna B Zimmer; Rena G Lapidus; David J Weber
Journal:  Methods Mol Biol       Date:  2013

Review 5.  Kinesin-5: cross-bridging mechanism to targeted clinical therapy.

Authors:  Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim
Journal:  Gene       Date:  2013-08-14       Impact factor: 3.688

6.  Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.

Authors:  Jessica A Yu; David Mauchley; Howard Li; Xianzhong Meng; Raphael A Nemenoff; David A Fullerton; Michael J Weyant
Journal:  J Thorac Cardiovasc Surg       Date:  2012-11       Impact factor: 5.209

7.  Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer.

Authors:  Meenakshi Malhotra; Catherine Tomaro-Duchesneau; Shyamali Saha; Satya Prakash
Journal:  Int J Biomater       Date:  2013-09-15

Review 8.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Enzo Di Fabrizio; Elisabetta Ferretti; Silverio Tomao; Alberto Gulino
Journal:  Int J Nanomedicine       Date:  2012-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.